8-K filing — Flyte Aviation, Inc. (VJET)
Filed: 2026-11-16 AccNo: 0001437749-26-037257 Size: 198 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-16 AccNo: 0001437749-26-037257 Size: 198 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Catheter Precision, a subsidiary of Flyte Aviation (NYSE American: VJET), published a peer-reviewed study in The Journal of Interventional Cardiology demonstrating that its LockeT suture retention device outperforms Abbott's Perclose vascular closure device. The 172-patient study showed LockeT achieved 1.2% access-site complications versus 9.3% for Perclose, with zero device failures compared to 4.7% for Perclose, while maintaining equivalent efficiency in hemostasis and same-day discharge rates.
Flyte Aviation (NYSE American: VJET) reported record Q3 2026 preliminary revenue of $2.15 million, up 110% quarter-over-quarter, with aviation segment revenue increasing 150% sequentially to $1.87 million. The company's redesigned digital booking platform surged 185% in user base to over 20,000 users since its May 2026 launch, generating over $500,000 in direct-to-consumer revenue in Q3. The company is expanding its fleet, entering Caribbean operations, and pursuing Canadian expansion.
Aviation revenue grew 150% sequentially, from Q2 2026, to approximately $1.87 millionProprietary digital aviation platform user base surges 185% since its redesign in late May 2026, adding more than 13,000 new accounts
Option Care Health jumped 23.8% on reports McKesson and CD&R may acquire it; Freight Technologies led gainers, while NFT Ltd. led decliners.